Nanofilament immunotherapy induces potent antitumor vaccine responses
Multimodal nanofilament immunotherapy is a novel approach to mounting systemic antitumor immune responses in situ by physically attaching large immunostimulatory molecules to cancer cells. TAT003 induced marked tumor regression by leveraging synergies between therapeutic agents displayed on its surface while offering a favorable tolerability profile. The results presented here establish multimodal nanofilaments as an innovative and versatile immunotherapy platform for developing in situ cancer vaccines.
Authors
- Lee‐Hwa Tai (ORCID: https://orcid.org/0000-0002-1176-4941)
- Melina Gonzalez
- Kevin Neil (ORCID: https://orcid.org/0000-0003-3529-2237)
- Hugo Giguère (ORCID: https://orcid.org/0000-0001-7193-0051)
- Vincent Quoc‐Huy Trinh
- Jean‐François Millau
- Lauren Daniel (ORCID: https://orcid.org/0009-0002-0847-4369)
- J Douchin
- Sébastien Rodrigue (ORCID: https://orcid.org/0000-0002-5366-7234)
- Samuel Génier (ORCID: https://orcid.org/0000-0002-5957-4012)
- Shujun Huang (ORCID: https://orcid.org/0000-0002-6994-1875)
- M Poisson
Institutions
- Université de Sherbrooke (CA)
- Institute for Research in Immunology and Cancer (CA)
- Centre Hospitalier de l’Université de Montréal (CA)
- Université de Montréal (CA)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-08-31
- DOI
- https://doi.org/10.1136/jitc-2024-011331
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Génome Québec